Skip to main content
. Author manuscript; available in PMC: 2007 Dec 10.
Published in final edited form as: Nicotine Tob Res. 2007 Dec;9(12):1251–1257. doi: 10.1080/14622200701705027

Figure 1.

Figure 1

Smoking cessation outcomes by treatment condition and DRD2 Taq1A genotype. Rate of biochemically verified 7-day point-prevalence abstinence at end of treatment and at 6- and 12-month follow-up assessments grouped by DRD2 Taq1 genotype and treatment condition (A1/A1 or A1/A2 on placebo: solid; A1/A1 or A1/A2 on bupropion: dashed; A2/A2 on placebo (PBO): dotted; A2/A2 on bupropion (BUP): dotted and dashed).